openPR Logo
Press release

HPAPI 2020 conference to discuss containment solutions and ADC developments

02-10-2020 12:29 PM CET | Media & Telecommunications

Press release from: SMi Group Ltd

HPAPI 2020 conference to discuss containment solutions and ADC

On the 11th - 12th May 2020, industry professionals will convene in London to discuss the challenges of the HPAPI industry at the Highly Potent Active Pharmaceutical Ingredients conference.
The global market for Highly Potent Active Pharmaceutical Ingredients has experienced an increased growth, resulting from its major use in oncology for cancer treatment - more often in the form of antibody drug conjugates (ADC).

With this in mind, one of the underlying subjects of the conference will be on containment solutions and ADC developments, where real-world examples of PBD payload synthesis, manufacture of oncology products and design of ADC containment systems will be discussed in fine detail. The conference will feature three briefings dedicated to these topics from leading industry professionals:

1) CMC Strategies for the Timely Launch Preparation of Antibody-Drug-Conjugates as High Potent APIs
o The manufacture of highly potent ADCs - challenges and solutions
o Deciding when to outsource and when to keep in-house
o Bayer's ADC production concept
o Best practices for CMO selection and outsourcing ADC development and manufacture
o The journey from development to launch - understanding the needs, solutions, risks and mitigations
Presented by Ulrich Ruemenapp, Head of Launch preparation and Coordination, Bayer Ag

2) Engineering in Support of ADC Containment - a Case Study
o Innovative solutions to dealing with increasing toxicity of ADCs
o Designing ADC containment systems
o The containment of ADCs - a case study from AZ
Presented by Peter Marshall, Associate Engineering Director, AstraZeneca

3) Manufacturing of Oncological Products: a Perspective by a CDMo
o New Product Introduction
o Cross Contamination Risk Assessment & Environmental Risk Assessment
o Case Study: ADC Manufacturing
Presented by Fabio Zenobi, EHS Director, BSP Pharmaceuticals

Interested parties can view the full agenda and register for the event online at http://www.highlypotentapi.com/pr2

--- END ---

Highly Potent Active Pharmaceutical Ingredients
Main conference: 11th-12th May 2020
Post-conference workshop day: 13th May 2020
London, UK
Sponsored by: BSP Pharmaceuticals

To sponsor or exhibit at the conference, please contact Alia Malick on +44 (0) 207 827 6748 or amalick@smi-online.co.uk.

For all delegate enquiries, contact Dylan Brohm on +44 (0) 20 7827 1024 or dbrohm@smi-online.co.uk.

1 Westminster Bridge Road

Event organisers

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HPAPI 2020 conference to discuss containment solutions and ADC developments here

News-ID: 1925337 • Views:

More Releases from SMi Group Ltd

Co-chairs invitation to attend the Pharmaceutical Cleanrooms Conference in London, UK
Co-chairs invitation to attend the Pharmaceutical Cleanrooms Conference in Londo …
SAE Media Group reports: Conference co-chairs invite you to attend the 2nd Annual Next Generation Pharmaceutical Cleanrooms this October 2022. The conference will be co-chaired by Conor Murray, Chairman, Irish Cleanroom Society and Connor McMorrow, Aseptic Lead Cell Therapy, Takeda, in which they have released an invitation letter for all interested parties. Excerpt of the Co-Chair invitation letter: 'As joint chairs of the 2nd Annual Next Generation Pharmaceutical Cleanrooms Conference, it is our
Exclusive Speaker Interview with Karen Capper, AstraZeneca ahead of the Pharmaceutical Microbiology UK Virtual Conference
Exclusive Speaker Interview with Karen Capper, AstraZeneca ahead of the Pharmace …
SMi Group reports: exclusive speaker interview with microbiology expert Karen Capper, AstraZeneca about the developments in the microbiology field. Now in its 10th Annual year, the Pharmaceutical Microbiology UK conference is one not to be missed. Taking place on 17th and 18th January 2022 as a virtual conference with online access only. The conference will bring together industry experts to discuss and analyse the latest advancements and challenges within pharmaceutical microbiology. Interested
SMi’s 3D Cell Culture conference 2022 – Speakers announced
SMi’s 3D Cell Culture conference 2022 – Speakers announced
SMi Reports: Agenda and speaker overview of the upcoming 5th Annual 3D Cell Culture Conference. SMi Group is delighted to announce the return of the successful 3D Cell Culture Conference for its 5th year, taking place on 9th and 10th February 2022 in London, UK. Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in
Maritime Safety Briefings to Look Forward to at Defence Safety 2020
Maritime Safety Briefings to Look Forward to at Defence Safety 2020
Defence Safety 2020 will provide a comprehensive overview of safety within the military, aiming to review the safe delivery of defence capabilities, and the parts that operational users, equipment, and service delivery organisations, as well as research and development play. Once again supported by the UK MoD Defence Safety Authority, the event will feature a diverse, international speaker line-up of military and industry experts, who will explore the latest updates on

All 5 Releases


More Releases for ADC

Latest Azodicarbonamide (ADC) Market 2022 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Azodicarbonamide (ADC) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Azodicarbonamide (ADC) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Azodicarbonamide (ADC) report includes a professional in-depth study
Global ADC Blowing Agents Market Analysis by 2020-2025
Global Info Research offers a latest published report on ADC Blowing Agents Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global ADC Blowing Agents Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report TOC, figure
ADC Blowing Agents Market Demand by 2025: QY Research
Global ADC Blowing Agents market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail information about
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends. This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering National Semiconductor Nippon Precision Circuits Inc Micro Analog systems Microchip Technology. TelCom Semiconductor, Inc Vishay Siliconix Texas
SMi’s inaugural ADC Summit, 23rd & 24th May 2012, London
Antibody Drug Conjugates are used to fight cancerous cells and are made up of the antibody that will target a specific tumour0-associated antigen a drug often described as payload and the linker. This results in a drug being delivered selectively to the appropriate malignant cell due to the antibody targeting and specific antigen With less than a month away, join SMi at their inaugural ADC Summit conference that will provide a
ADC African Development Corporation GmbH & Co. KGaA: ADC exits shareholding in E …
ADC African Development Corporation (ADC), ISIN DE000A1E8NW9, a fast growing financial services group focusing on the frontier markets of sub-Saharan Africa, has successfully negotiated an exit for its 11.5% shareholding in Ecobank Zimbabwe for USD 5.2 million equaling approx. EUR 4.0 million. As of 30 September 2011, ADC had valued its shareholding in Ecobank Zimbabwe at EUR 1.25 million, so this transaction results in a realized profit of EUR 2.75